Company CVAbout Welcure Drugs & Pharmaceuticals Ltd 
Welcure Drugs & Pharmaceuticals Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Incorporated on 4 Jun.'92, Welcure Drugs And Pharmaceuticals (WDPL) was promoted by D C Jain, Sanjeev Jain and Sandeep Jain. The promoters have interests in other companies such as Paam Pharmaceuticals, Pioneer Products, Alirox Abrasives, A K Laboratories, etc. WDPL had come out with a Rs 4-cr public issue in Aug.'94 to part-finance the Rs 7-cr project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary, A K Laboratories (AKL).
Company Coordinates
Company Details
B-9 & 10 Laxmi Towers, L S C Block-C Saraswati Vihar Delhi New Delhi : 110034
Registrar Details
Link Intime India Pvt Ltd., Narang Tower 44, Community Centre, Naraina Industrial Area , Phase - 1, New Delhi
Capital StructureCapital Structure
Present Equity Capital
INR 123.59 Cr
Number of Shares
12.36 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
16-Oct-2025
12.36
123.59
11235820
10
Bonus Issue
16-Oct-2025
123.59
123.59
1112346180
1
Stock Split
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Non Institution
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 0 FIIs
Promoter with highest holding
None
Highest Public shareholder
Techroxy Solution Private Limited (1.78%)
Individual Investors Holdings
91.83%
Board of Directors
Management
Designation
Remuneration
D C Jain
Non-Exec & Non-Independent Dir
0
Sudhir Chandra
Managing Director
1.29 lacs
Mitashi Bisaria
Director & Company Secretary
8.0 k
Gagan Juneja
Non-Exec. & Independent Dir.
8.0 k
Mohd. Shahbaz Alam
Independent Director
4.0 k
Sitaben S Patel
Additional Director
0
Rajeev Mehra
Additional Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Other Operating Revenues-Commission Income
0.08
100.00%
Other Operating Revenues-Commission Income
Stock DNARevenue and Profits:
Net Sales:
66 Cr
(Quarterly Results - Sep 2025)
Net Profit:
8 Cr
Pharmaceuticals & Biotechnology
INR 67 Cr (Micro Cap)
2.00
34
0.00%
1.20
33.54%
0.64
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
